User:Mr. Ibrahem/Dabigatran

Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests. It is taken by mouth.

Common side effects include bleeding and gastritis. Other side effects may include bleeding around the spine and allergic reactions such as anaphylaxis. In cases of severe bleeding, it can be reversed with the antidote, idarucizumab. Use is not recommended during pregnancy or breastfeeding. Compared to warfarin it has fewer interactions with other medications. It is a direct thrombin inhibitor.

Dabigatran was approved for medical use in the United States in 2010. It is on the World Health Organization's List of Essential Medicines. A month supply in the United Kingdom costs the NHS about GB£51 as of 2019. In the United States the wholesale cost of this amount is about US$416. In 2017, it was the 302nd most commonly prescribed medication in the United States, with more than one million prescriptions.